scholarly journals The role of nasal IgA in children vaccinated with live attenuated influenza vaccine

Vaccine ◽  
2012 ◽  
Vol 30 (48) ◽  
pp. 6794-6801 ◽  
Author(s):  
Christopher S. Ambrose ◽  
Xionghua Wu ◽  
Taff Jones ◽  
Raburn M. Mallory
Keyword(s):  
Influenza Vaccine ◽  
Live Attenuated Influenza Vaccine

Nontraditional Uses of Live Attenuated Influenza Vaccine: School-Located Influenza Vaccination

2020 ◽  
Vol 9 (Supplement_1) ◽  
pp. S19-S23 ◽  
Author(s):  
Geoffrey A Weinberg
Keyword(s):  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Influenza Infection ◽  
Evidence Base ◽  
Vaccine Effectiveness ◽  
Vaccination Rates ◽  
Live Attenuated Influenza Vaccine

Abstract Immunization against influenza continues to be the best method of preventing influenza infection in children, and additionally, indirectly helping to lower disease in adults, given the role of children as “spreaders” of influenza to the community at large. An increasing evidence base exists for the use of school-located influenza vaccination (SLIV) programs to increase the influenza vaccination rates among children. Live, attenuated influenza vaccine (LAIV) has unique characteristics that make it useful for SLIV programs, including ease of immunization without needles, faster delivery, and in many (but not all) years, good vaccine effectiveness. Reviewed herein are results of selected published trials as well as guidance on planning a successful SLIV program.

Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets

Vaccine ◽  
2011 ◽  
Vol 29 (16) ◽  
pp. 2887-2894 ◽  
Author(s):  
Melissa B. Pearce ◽  
Jessica A. Belser ◽  
Katherine V. Houser ◽  
Jacqueline M. Katz ◽  
Terrence M. Tumpey
Keyword(s):  
Influenza Vaccine ◽  
Virus Replication ◽  
H1n1 Virus ◽  
Live Attenuated Influenza Vaccine ◽  
2009 H1n1

scholarly journals High-Affinity H7 Head and Stalk Domain–Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine

2015 ◽  
Vol 212 (8) ◽  
pp. 1270-1278 ◽  
Author(s):  
Jessica L. Halliley ◽  
Surender Khurana ◽  
Florian Krammer ◽  
Theresa Fitzgerald ◽  
Elizabeth M. Coyle ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Specific Antibody ◽  
Antibody Responses ◽  
Domain Specific ◽  
High Affinity ◽  
Live Attenuated Influenza Vaccine ◽  
Stalk Domain

scholarly journals Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results

2016 ◽  
Vol 21 (38) ◽  
Author(s):  
Richard Pebody ◽  
Fiona Warburton ◽  
Joanna Ellis ◽  
Nick Andrews ◽  
Alison Potts ◽  
...  
Keyword(s):  
Primary Care ◽  
United Kingdom ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Immunisation Programme ◽  
Influenza B ◽  
Live Attenuated Influenza Vaccine ◽  
The United Kingdom ◽  
Influenza A H1n1 ◽  
The Uk

The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season’s adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0–61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6–64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6) against influenza B. In 2–17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6–94.3) against influenza B and 41.5% (95% CI: −8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.

Sign in / Sign up

Export Citation Format

Share Document